TRACON Pharmaceuticals Inc
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 Ig… Read more
TRACON Pharmaceuticals Inc (TCON) - Total Assets
Latest total assets as of June 2024: $7.40 Million USD
Based on the latest financial reports, TRACON Pharmaceuticals Inc (TCON) holds total assets worth $7.40 Million USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TRACON Pharmaceuticals Inc - Total Assets Trend (2012–2023)
This chart illustrates how TRACON Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
TRACON Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
TRACON Pharmaceuticals Inc's total assets of $7.40 Million consist of 90.0% current assets and 10.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 84.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2023)
This chart illustrates how TRACON Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TRACON Pharmaceuticals Inc's current assets represent 90.0% of total assets in 2023, a decrease from 98.9% in 2012.
- Cash Position: Cash and equivalents constituted 84.8% of total assets in 2023, down from 94.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
TRACON Pharmaceuticals Inc Competitors by Total Assets
Key competitors of TRACON Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
TRACON Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - TRACON Pharmaceuticals Inc generates 1.19x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - TRACON Pharmaceuticals Inc is currently not profitable relative to its asset base.
TRACON Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.66 | 0.41 | 1.58 |
| Quick Ratio | 0.66 | 0.41 | 1.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.38 Million | $ -16.08 Million | $ 7.44 Million |
TRACON Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between TRACON Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.83 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -48.1% |
| Total Assets | $10.11 Million |
| Market Capitalization | $107.83K USD |
Valuation Analysis
Below Book Valuation: The market values TRACON Pharmaceuticals Inc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: TRACON Pharmaceuticals Inc's assets decreased by 48.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for TRACON Pharmaceuticals Inc (2012–2023)
The table below shows the annual total assets of TRACON Pharmaceuticals Inc from 2012 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $10.11 Million | -48.10% |
| 2022-12-31 | $19.47 Million | -26.69% |
| 2021-12-31 | $26.56 Million | -29.06% |
| 2020-12-31 | $37.44 Million | +106.60% |
| 2019-12-31 | $18.12 Million | -55.42% |
| 2018-12-31 | $40.65 Million | +12.50% |
| 2017-12-31 | $36.13 Million | -20.99% |
| 2016-12-31 | $45.73 Million | -14.56% |
| 2015-12-31 | $53.52 Million | +40.22% |
| 2014-12-31 | $38.17 Million | +1477.97% |
| 2013-12-31 | $2.42 Million | -7.35% |
| 2012-12-31 | $2.61 Million | -- |